Literature DB >> 11687851

Role of cystatin C and cysteine proteinases in the development of mouse LS-lymphosarcoma.

O N Poteryaeva1, O V Falameeva, S Y Zhanaeva, I G Svechnikova, T A Korolenko, V I Kaledin.   

Abstract

The growth of LS-lymphosarcoma in CBA mice was accompanied by a decrease in the content of the major extracellular inhibitor cystatin C in the tumor, plasma and, to a lesser extent, in tissues not involved in tumor process (liver and spleen). Cyclophosphamide in a dose of 50 mg/kg prolonged the life-span of animals and decreased tumor size by 80%. Cathepsin B and L activities in the tumor tissue increased by 3 and 7 times, respectively. Cystatin C content in the tumor tissue, spleen, and plasma also increased. Cystatin C assay in tumor tissue and plasma helps to predict the rate of tumor growth and to evaluate the efficiency of antitumor therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11687851     DOI: 10.1023/a:1012584429734

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  3 in total

1.  A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation.

Authors:  Ekaterina A Alyamkina; Valeriy P Nikolin; Nelly A Popova; Evgenia V Dolgova; Anastasia S Proskurina; Konstantin E Orishchenko; Yaroslav R Efremov; Elena R Chernykh; Alexandr A Ostanin; Sergey V Sidorov; Dmitriy M Ponomarenko; Stanislav N Zagrebelniy; Sergey S Bogachev; Mikhail A Shurdov
Journal:  Genet Vaccines Ther       Date:  2010-11-01

2.  Nuclear Factor kappa B is central to Marek's disease herpesvirus induced neoplastic transformation of CD30 expressing lymphocytes in-vivo.

Authors:  Shyamesh Kumar; Dusan Kunec; Joram J Buza; Hsin-I Chiang; Huaijun Zhou; Sugalesini Subramaniam; Ken Pendarvis; Hans H Cheng; Shane C Burgess
Journal:  BMC Syst Biol       Date:  2012-09-14

3.  Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis.

Authors:  P Strojan; I Oblak; B Svetic; L Smid; J Kos
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.